Updated time: 2024-02-20 15:28:19
10A-1081029
2020-06-03
TW I828951
PD-L1/PD-1 inhibitors have shown promise as a treatment modality for non-small-cell lung carcinoma (NSCLC). Therefore, understanding the mechanisms of PD-L1 regulation may assist the development of combination therapies to improve the efficacy of current NSCLC treatments. In this study, we found that PD-L1 stability is promoted by EpCAM expression, especially the extracellular domain (EpEX). Importantly, an EpCAM neutralizing antibody, EpAb2-6, decreased PD-L1 protein level and enhanced cytotoxic actions of CD8+ T cells in vitro. In animal model, EpAb2-6 treatment inhibited tumor growth and increased the number of CD8+ T cells in the tumor microenvironment. Moreover, a combination of Atezolizumab and EpAb2-6 showed markedly enhanced therapeutic efficacy and more tumor-localized CD8+ T cells compared to Atezolizumab alone. In conclusion, our results reveal that EpCAM stabilizes PD-L1 protein through EGFR-ERK signaling and suggests a promising new combination strategy for NSCLC immunotherapy.
- It was first discovered that EpCAM can regulate the stability of PD-L1.
- Blocking EpCAM signaling by antibodies (EpAb2-6) or small molecule drugs increases the efficacy of PD-1/PD-L1 inhibitors.
- For lung cancer patients who currently use PD-1/PD-L1 inhibitors are not effective.
- Blocking EpCAM signaling by antibodies (EpAb2-6) or small molecule drugs promotes the efficacy of PD-1/PD-L1 inhibitors.
Han-Chung Wu
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

EpCAM/EpEX signaling promotes PD-L1 stability through EGFR-ERK signaling in lung cancer cells